S-4327-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Tom Cotton (R-AR)
What it does
This bill would take steps to reduce U.S. reliance on China for pharmaceutical drugs and drug ingredients. Based on its title, it would likely impose restrictions, tariffs, or sourcing requirements on pharmaceuticals manufactured in or sourced from China. The full legislative text was not provided, so the specific mechanisms — such as import bans, domestic manufacturing incentives, or procurement rules — cannot be confirmed from the text alone.
Who benefits
U.S.-based pharmaceutical manufacturers and active pharmaceutical ingredient (API) producers who would gain competitive advantage over Chinese suppliers. Workers in domestic drug manufacturing facilities. Communities where new or expanded domestic production facilities might be built. Patients and public health officials concerned about supply chain vulnerabilities. National security and defense interests reliant on a stable domestic drug supply.
Who is hurt
Pharmaceutical companies that currently source ingredients or finished drugs from China and would face higher costs or supply disruptions. Patients and insurers who may face higher drug prices if cheaper Chinese-sourced inputs are restricted. Generic drug manufacturers, who rely heavily on Chinese APIs, could face significant cost increases. Importers and distributors in the pharmaceutical supply chain. Chinese pharmaceutical exporters and their U.S. business partners.
Supporters argue
Supporters argue that the U.S. is dangerously dependent on China for critical drug ingredients — estimates suggest China supplies roughly 80% of the APIs used in U.S. generic drugs — creating a national security vulnerability that could be exploited during a conflict or diplomatic crisis. They contend that reducing this dependence through domestic sourcing requirements or import restrictions is a necessary step to ensure Americans have reliable access to life-saving medications, as demonstrated by supply disruptions experienced during the COVID-19 pandemic.
Opponents argue
Opponents argue that restricting Chinese pharmaceutical imports would raise drug costs for American patients and insurers, since Chinese-sourced APIs are often significantly cheaper than domestic or allied-nation alternatives, and that the U.S. generic drug market — which fills roughly 90% of prescriptions — depends on low-cost inputs to remain affordable. They contend that abrupt supply chain restrictions could cause drug shortages in the near term before domestic capacity can be built up, potentially harming the very patients the bill aims to protect.